Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

09/19
2017

Clinical Trial News from UCLA

UCLA Clinical Trials news for September, 2017 News on 4 Clinical Trials at UCLA and TRIO-US facilities: 1. Phase 3 Trial for EGFRm Positive NSCLC Now Open UCLA  announces the opening of CheckMate 722, a phase 3 trial for pati…

09/12
2017

We’re more likely to get cancer than to get married.

This is a wake-up call. One in two people will encounter a cancer diagnosis in their lifetime, which is why a recent report says that, alongside marriage, parenthood, retirement and the death of a parent, cancer is now “a common life mile…

09/12
2017

Opdivo Improves Long-Term Survival in Advanced Lung Cancer

Opdivo outperformed the cancer drug Taxotere in clinical trials of advanced and earlier treated lung cancer. All patients received the treatment as a second line, following one failed platinum-based chemotherapy regimen. The study loo…

09/12
2017

Lung Cancer: Is Your Doctor Screening You for the Best Treatment?

Not every eligible lung cancer patient receives the new, lifesaving therapies they should. Here’s what’s going on and how to keep it from happening to you. Learn More…

09/12
2017

Merck’s immunotherapy, chemo mix shows extended lung cancer gains

Keytruda plus chemo still shows clear benefit 18 months on: Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical…

09/7
2017

Blood tumor markers may warn when lung cancer patients are progressing

New study suggests that tumor markers could be useful in monitoring therapeutic outcomes in those with already established NSCLC disease. Learn More…

09/1
2017

Pembrolizumab Shows Promise in Small Cell Lung Cancer

Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 33% in patients with extensive-stage small cell lung cancer (SCLC), according to findings from the open-label, phase Ib KEYNOTE-028 trial published in the Journal of Clinica…

09/1
2017

Changing Treatment Paradigm for ALK-Positive Lung Cancer

The results of recent clinical trials signal a shifting treatment paradigm that moves away from chemotherapy and crizotinib toward next-generation ALK inhibitors as first line therapy for patients with advanced ALK-positive NS…

09/1
2017

Blood test can predict early lung cancer prognosis

Cancer cells obtained from a blood test may be able to predict how early-stage lung cancer patients will fare, a team from the University of Michigan has shown. Learn More More on Liquid Biopsy How do you know if you are at risk fo…

08/29
2017

Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths

Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths: Treatment that targeted inflammation in the postmyocardial infarction (post-MI) setting led to a thought-provoking reduction in lung cancer incidence and mortality, according t…

08/18
2017

Blood Test Finds Cancer Before Symptoms Start

Blood Test Finds Cancer Before First Symptoms Start: From NBC News Researchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up. The blood test detec…

08/18
2017

Newly Diagnosed with Lung Cancer? Get a Second Opinion

The idea of getting a second opinion after a lung cancer diagnosis may make you feel uncomfortable. But cancer organizations, including the American Society of Clinical Oncology and the Lung Cancer Foundation of America, say second opinions…

08/15
2017

Too Many Drugs in Too Many Trials and Not Enough Patients?

Too Many Drugs,Too Many Trials, Not Enough Patients With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented i…

08/14
2017

Lung cancer diagnosis increases suicide risk by 420%

Lung cancer diagnosis increases suicide risk by 420%, according to a recent study. HemOncToday says: Patients with lung cancer appeared more than four times as likely to commit suicide as individuals in the general population, accordi…

08/14
2017

New Trial for NSCLC Patients with no Previous Immunotherapy Opens

New Trial for NSCLC Patients with no Previous Immunotherapy Opens According to the Thoracic Oncology Translational Research Patient Newsletter, UCLA is happy to announce that the BMS CA209-817 Trial is now open for second-line NSCLC patient…

08/8
2017

Alecensa Gets Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Alecensa for ALK-Positive Lung Cancer: Priority Review For Treatment from Business Wire Second positive Phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lower…

07/25
2017

Changes to Improve Usability of ClinicalTrials.gov

Improve usability of clinicaltrials.gov: The National Institutes of Health website to search for clinical trials is undergoing a series of changes focused on improving the ability to search, display, and review information about clinical t…

07/14
2017

New CDC Report Shows Deaths from Cancer Higher in Rural America

The CDC's July 7, 2017                       Morbidity and Mortality Weekly Report shows a slower reduction in cancer death rates in rural America comp…

07/6
2017

Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma

Good news for Mesothelioma patients: FDA approves Tagrisso for lung cancer patients with the EGFR T790M mutation. Learn More…

06/27
2017

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V60…

06/20
2017

With Patients Reporting Symptoms Using Web Tool, Survival Improves

An online tool that allows metastatic cancer patients to report their symptoms and grade them on severity is helping improve their survival, according to a study reported at the recent meetings of the American Society of Clinical Oncology m…

06/7
2017

Combined immune checkpoint blockade shows promise for small cell lung cancer

Small Cell Lung Cancer news: The combination of nivolumab plus ipilimumab led to durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial presented at the 2017 ASCO Annu…

06/7
2017

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Learn more More Lung Cancer Research News:…

05/22
2017

Lab on a Chip Outlines New Liquid Biopsy Technology

Lab on a Chip publication outlines a new technology that may be an important tool for liquid biopsies. Read the UCLA Patient Newsletter Read the abstract…

05/18
2017

Improved Survival Using Imfinzi In Sequential Treatment in NSCLC

A newly released study shows that Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not pro…

05/12
2017

FDA Approves Keytruda Combo for Lung Cancer

The Food and Drug Administration (FDA) has granted an accelerated approval to Keytruda (pembrolizumab) for use in combination with chemotherapy as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell l…

05/4
2017

Brigatinib

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progress…

05/1
2017

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

[caption id="attachment_1562" align="aligncenter" width="850"] Senior woman with lung cancer during medical visit[/caption] FDA Grants Lorlatinib Breakthrough Designation for NSCLC: “This regulatory designation recognizes the potential for…

04/28
2017

DNA-based test can spot cancer recurrence a year before conventional scans

DNA-based test spots cancer recurrence : A revolutionary blood test has been shown to diagnose the recurrence of cancer up to a year in advance of conventional scans in a major lung cancer trial. Read more…

04/18
2017

Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for…

04/18
2017

AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act

Can we make the ACA better? The legislation was the focus of a panel held at the American Association for Cancer Research Annual Meeting 2017. Read more: http://blog.aacr.org/aacr-annual-meeting-2017-panel-discusses-affordable-care-a…

04/18
2017

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

  Are responses to immunotherapy for lung cancer durable? According to data presented at AACR's 2017 Annual Meeting, from a number of clinical trials, the answer appears to be “Yes.” For many patients whose cancers responded …

04/11
2017

Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

A recent study shows that Alecensa® as an initial (first-line) treatment significantly reduced the risk of disease worsening or death compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell …

04/5
2017

Drug Offers Some Hope for a Deadly Lung Cancer

The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years …

03/27
2017

‘Bad luck’ mutations increase cancer risk more than behavior, study says

For the first time, researchers have estimated what percentage of cancer mutations are due to environmental and lifestyle factors, hereditary factors and random chance. Overall, 66% of the genetic mutations that develop into cancer are caused…

03/16
2017

Frontline Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to des…

03/14
2017

Advice From Patients On A Study’s Design Makes For Better Science

Clinical Trials News:  NCI-MATCH trial upends the normal way of classifying cancers for treatment: Instead of categorizing malignancies by the organ where they first appear, this method of sorting focuses on particular mutations in the ge…

03/7
2017

Update: CRISPR

Scientists say they’ll someday be able to use CRISPR to fight cancer and maybe even bring animals back from the dead. Read the story: http://www.radiolab.org/story/update-crispr/…

02/14
2017

Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…

01/27
2017

Stand Up To Cancer Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception…



Read More